Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Maribavir for Cytomegalovirus Infection in Lymphoid Malignancy Patients Receiving Bispecific Antibody Therapy
KCT0012079Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on KCT0012079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012079.